GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Revenue per Share

BridgeBio Pharma (BridgeBio Pharma) Revenue per Share : $0.06 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Revenue per Share?

BridgeBio Pharma's revenue per share for the three months ended in Dec. 2023 was $0.01. BridgeBio Pharma's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.06.

Warning Sign:

BridgeBio Pharma Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of BridgeBio Pharma was -89.20% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for BridgeBio Pharma's Revenue per Share or its related term are showing as below:

BBIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.6   Med: 2.15   Max: 10.9
Current: -6.6

During the past 7 years, BridgeBio Pharma's highest 3-Year average Revenue Per Share Growth Rate was 10.90% per year. The lowest was -6.60% per year. And the median was 2.15% per year.

BBIO's 3-Year Revenue Growth Rate is ranked worse than
67.79% of 770 companies
in the Biotechnology industry
Industry Median: 5.4 vs BBIO: -6.60

BridgeBio Pharma Revenue per Share Historical Data

The historical data trend for BridgeBio Pharma's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Revenue per Share Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial 0.39 0.07 0.48 0.53 0.06

BridgeBio Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.03 0.01

Competitive Comparison of BridgeBio Pharma's Revenue per Share

For the Biotechnology subindustry, BridgeBio Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Pharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's PS Ratio falls into.



BridgeBio Pharma Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

BridgeBio Pharma's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=9.303/162.792
=0.06

BridgeBio Pharma's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=1.745/174.493
=0.01

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BridgeBio Pharma  (NAS:BBIO) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


BridgeBio Pharma Revenue per Share Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BridgeBio Pharma (BridgeBio Pharma) Business Description

Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Executives
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick officer: Chairman of Oncology C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Neil Kumar director, officer: See Remarks C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson officer: See Remarks 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille director 175 WATER STREET, NEW YORK NY 10038
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels director C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee director 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders director 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis director C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Richard H Scheller director, officer: See Remarks C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990

BridgeBio Pharma (BridgeBio Pharma) Headlines